NCT04322578

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Hunan Province Tumor Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer

Detailed description

This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer . All the clinical and survival data will be collected for full analysis.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Crizotinib	Crizotinib 250mg po bid. Savolitinib 300mg po, qd.
DRUG	Pemetrexed	Pemetrexed, 500mg/m2, ivgtt erery 21day.

Timeline

• Start date: 2020-03-24
• Primary completion: 2025-03-24
• Completion: 2026-03-24
• First posted: 2020-03-26
• Last updated: 2024-06-04

Locations

1 site across 1 country: China